JonesResearch analyst Justin Walsh initiated coverage of VolitionRx (VNRX) with a Buy rating and $3 price target VolitionRx is a commercial-stage epigenetics company leveraging nucleosomes and transcription factors to diagnose and monitor human and animal health, the analyst tells investors in a research note. The firm believes the company’s strategy to drive widespread adoption of its patent-protected portfolio of Nu.Q assays via collaborations with major marketing partners in the human and animal health spaces is achievable and could drive “highly favorable” operating margins.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX:
- Tomi Environmental Solutions appoints Vanston as CFO
- VolitionRX Ltd. Earnings Call Reveals Promising Growth
- VolitionRx Reports Strong Q1 2025 Performance
- VolitionRX’s Promising Growth: Buy Rating Backed by Revenue Surge and Strategic Partnerships
- Options Volatility and Implied Earnings Moves Today, May 16, 2025